NCT05069623 - A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 16, 2022

Study Completion Date

May 30, 2023

Conditions

COVID-19Infection ViralInfections

Interventions

BIOLOGICAL

VB10.2129

0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0

BIOLOGICAL

VB10.2210

3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0

Trial Locations (2)

Haukeland University Hospital, Klinisk Forskningspost, Bergen

Oslo University Hospital Ullevål Sykehus, Dept. Infection Diseases, Oslo